Schlokat U, Fischer B E, Herlitschka S, Antoine G, Preininger A, Mohr G, Himmelspach M, Kistner O, Falkner F G, Dorner F
Biomedical Research Center, IMMUNO AG, Austria.
Biotechnol Appl Biochem. 1996 Dec;24(3):257-67.
Recombinant human von Willebrand Factor (rvWF), a multimeric glycoprotein essential to haemostasis, has been developed as a potential therapeutic agent for treatment of von Willebrand disease (vWD). Permanent Chinese-hamster ovary (CHO)-rvWF cell clones co-expressing recombinant furin (rfurin) were established in order to ensure complete rvWF propeptide removal [Fischer, Schlokat, Mitterer, Reiter, Mundt, Turecek, Schwarz and Dorner (1995) FEBS Lett. 375, 259-262]. Large quantities of material are required for in vivo tests and clinical studies. This demand is commonly met by achieving high-yield expression of the desired protein via amplification. Co-amplification of rfurin, necessary to completely process increasing amounts of rvWF precursor, could not be accomplished, presumably due to lethal effects of overexpressed rfurin for the host cells [Creemers (1994) Ph.D. Thesis, University of Leuven]. Recent reports have inferred that rfurin can only mediate rvWF processing intracellularly [Rehemtulla and Kaufman (1992) Blood 79, 2349-2355; Rehemtulla, Dorner and Kaufman (1992) Proc. Natl. Acad. Sci. U.S.A. 89, 8235-8239]. We report here that rvWF-precursor processing, however, occurs predominantly extracellularly upon rfurin co-expression. Mixing experiments employing rfurin- as well as rvWF-precursor-containing conditioned media demonstrate that rvWF precursors are accessible and cleavable by rfurin in vitro. Exposure to rfurin in vitro converts the heterogeneous multimer pattern typical of incompletely processed rvWF multimers into highly homogeneous and structurally intact multimers superior to the ones exhibited by plasma-derived vWF. These findings thus demonstrate the feasibility of large-scale production of a completely processed, intact and homogeneous rvWF preparation, based on individual rvWF-precursor high-yield expression and subsequent propeptide removal by rfurin in vitro.
重组人血管性血友病因子(rvWF)是一种对止血至关重要的多聚体糖蛋白,已被开发为治疗血管性血友病(vWD)的潜在治疗剂。为确保rvWF前肽完全去除,建立了共表达重组弗林蛋白酶(rfurin)的永久性中国仓鼠卵巢(CHO)-rvWF细胞克隆[菲舍尔、施洛卡特、米特勒尔、赖特、蒙德特、图雷切克、施瓦茨和多纳(1995年)《欧洲生物化学学会联合会快报》375卷,第259 - 262页]。体内试验和临床研究需要大量材料。通常通过扩增实现所需蛋白质的高产表达来满足这一需求。由于过量表达的rfurin对宿主细胞具有致死作用,无法完成对不断增加的rvWF前体进行完全加工所需的rfurin共扩增[克里默斯(1994年)鲁汶大学博士论文]。最近的报告推断,rfurin只能在细胞内介导rvWF加工[雷赫姆图拉和考夫曼(1992年)《血液》79卷,第2349 - 2355页;雷赫姆图拉、多纳和考夫曼(1992年)《美国国家科学院院刊》89卷,第8235 - 8239页]。然而,我们在此报告,在rfurin共表达时,rvWF前体加工主要发生在细胞外。使用含有rfurin以及rvWF前体的条件培养基进行的混合实验表明,rvWF前体在体外可被rfurin接近并切割。体外暴露于rfurin可将未完全加工rvWF多聚体典型的异质多聚体模式转化为高度均一且结构完整的多聚体,优于血浆来源的vWF所呈现的多聚体。因此,这些发现证明了基于单个rvWF前体的高产表达以及随后通过体外rfurin去除前肽来大规模生产完全加工、完整且均一的rvWF制剂的可行性。